This company listing is no longer active
Generex Biotechnology Past Earnings Performance
Past criteria checks 0/6
Key information
-40.9%
Earnings growth rate
8.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -65.8% |
| Return on equity | n/a |
| Net Margin | -5,378.7% |
| Last Earnings Update | 30 Apr 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Generex Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 21 | 1 | -37 | 30 | 5 |
| 31 Jan 21 | 1 | -52 | 28 | 4 |
| 31 Oct 20 | 2 | -35 | 26 | 3 |
| 31 Jul 20 | 3 | -33 | 18 | 2 |
| 30 Apr 20 | 2 | -26 | 23 | 2 |
| 31 Jan 20 | 3 | -31 | 25 | 2 |
| 31 Oct 19 | 5 | -36 | 27 | 2 |
| 31 Jul 19 | 6 | -9 | 25 | 2 |
| 30 Apr 19 | 6 | 10 | 15 | 2 |
| 31 Jan 19 | 5 | 24 | 10 | 1 |
| 31 Oct 18 | 2 | 27 | 4 | 1 |
| 31 Jul 18 | 1 | 36 | 2 | 1 |
| 30 Apr 18 | 1 | 9 | 2 | 1 |
| 31 Jan 18 | 1 | -37 | 2 | 1 |
| 31 Oct 17 | 0 | -43 | 1 | 1 |
| 31 Jul 17 | 0 | -70 | 1 | 0 |
| 30 Apr 17 | 0 | -60 | 1 | 0 |
| 31 Jan 17 | 0 | -17 | 0 | 0 |
| 31 Oct 16 | 0 | -1 | 0 | 0 |
| 31 Jul 16 | 0 | -3 | 1 | 0 |
| 30 Apr 16 | 0 | -2 | 2 | 1 |
| 31 Jan 16 | 0 | -4 | 2 | 1 |
| 31 Oct 15 | 0 | -4 | 3 | 1 |
Quality Earnings: GNBT is currently unprofitable.
Growing Profit Margin: GNBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GNBT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GNBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: GNBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.